New tech drives huge growth in vaccine business
A revolution in genomics and molecular biology has spurred a burst of new development activity in the vaccines business. Analysts say that a slew of new products will propel 18 percent annual growth in the sector as the vaccine business swells from $13 billion to $30 billion in 2011. Merck, AstraZeneca, Pfizer and Sanofi-Aventis are all pursuing ambitious new programs.
- read the article from Forbes on the vaccine revolution
Related Articles:
Big Pharma takes an interest in cancer vaccines. Report
New approach to vaccine development. Report
Vaccine "renaissance" attracts huge new venture investments. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
